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Key messages
What is the key question?
 ► Are there sufficient grounds to justify larger 
randomised controlled trials of proton pump 
inhibitors in idiopathic pulmonary fibrosis 
(IPF) on the basis of feasibility and safety, and 
is cough a potential outcome measure for 
efficacy?
What is the bottom line?
 ► Omeprazole is well-tolerated and may have 
a positive effect on cough in IPF, suggesting 
larger trials are feasible but they will require 
screening of large numbers of patients and 
careful monitoring of adverse events, with 
particular reference to frequency of respiratory 
infections and changes in lung function.
Why read on?
 ► Controversy has surrounded the dual issues of 
whether proton pump inhibitors are beneficial 
in IPF and whether symptom-centred primary 
outcome measures can be usefully integrated 
when assessing new treatments for IPF—this 
study provides positive new information 
addressing both questions and outlines 
challenges in planning larger, definitive trials.
AbsTrACT
background cough is a common, disabling symptom 
of idiopathic pulmonary fibrosis (iPF), which may be 
exacerbated by acid reflux. inhibiting gastric acid 
secretion could potentially reduce cough. this study 
aimed to determine the feasibility of a larger, multicentre 
trial of omeprazole for cough in iPF, to assess safety and 
to quantify cough.
Methods Single-centre, double-blind, randomised, 
placebo-controlled pilot trial of the proton pump 
inhibitor (PPi) omeprazole (20 mg twice daily for 3 
months) in patients with iPF. Primary objectives were to 
assess feasibility and acceptability of trial procedures. the 
primary clinical outcome was cough frequency.
results Forty-five participants were randomised (23 
to omeprazole, 22 to placebo), with 40 (20 in each 
group) having cough monitoring before and after 
treatment. 280 patients were screened to yield these 
numbers, with barriers to discontinuing antacids the 
single biggest reason for non-recruitment. recruitment 
averaged 1.5 participants per month. geometric mean 
cough frequency at the end of treatment, adjusted for 
baseline, was 39.1% lower (95% ci 66.0% lower to 
9.3% higher) in the omeprazole group compared with 
placebo. Omeprazole was well tolerated and adverse 
event profiles were similar in both groups, although there 
was a small excess of lower respiratory tract infection 
and a small fall in forced expiratory volume and forced 
vital capacity associated with omeprazole.
Conclusions a large randomised controlled trial of 
PPis for cough in iPF appears feasible and justified but 
should address barriers to randomisation and incorporate 
safety assessments in relation to respiratory infection and 
changes in lung function.
InTroduCTIon
Idiopathic pulmonary fibrosis (IPF) is a chronic, 
fibrosing interstitial lung disease (ILD) character-
ised by progressive dyspnoea and cough. Chronic 
cough is a major and disabling symptom affecting 
up to 80% of patients with IPF,1 and a strong 
correlation has been demonstrated between objec-
tive cough frequency and health-related quality of 
life.2 Nevertheless, treatment of cough associated 
with IPF remains notoriously difficult and conven-
tional antitussive treatments have limited thera-
peutic effect.3
Gastro-oesophageal reflux disease (GORD) is 
more prevalent in patients with IPF compared with 
the general population and those with other chronic 
lung diseases,4 and a large proportion of patients 
with IPF have asymptomatic reflux disease.5–7 
GORD has been postulated as a contributory factor 
to chronic cough in IPF and to the overall patho-
genesis and progression of the disease. The use of 
antacid strategies such as proton pump inhibitors 
(PPIs) has therefore been commonplace in many 
countries and conditional recommendations for 
antacid treatment have been incorporated into 
current guidelines.8
Despite the frequent use of antacid therapy 
in this population, there are currently no large, 
randomised controlled trials (RCTs) evaluating the 
efficacy of PPIs in relation to cough frequency in 
IPF, and assessing their safety. This pilot trial was 
therefore designed to assess the feasibility of an 
RCT of omeprazole in IPF, with particular refer-
ence to safety and whether any potential effect on 
cough would emerge. Ultimately, the aim of the 
study was to determine whether a larger definitive 
multicentre trial is practicable and worthwhile and, 
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if so, to define possible barriers that should be addressed during 
trial design.
MeThods
study design and participants
A single-centre, double-blind, placebo-controlled, randomised 
pilot trial of omeprazole in patients with IPF was conducted 
at the Newcastle upon Tyne Hospitals NHS Foundation Trust. 
Participants aged 40–85 years with IPF were recruited from the 
ILD clinic at the Royal Victoria Infirmary, Newcastle upon Tyne, 
UK. Patients could also be identified and referred for participa-
tion from one of six Participant Identification Centres (PICs) by 
their treating clinicians.
A pragmatic clinical definition of IPF was used, in which partic-
ipants were required to fulfil all of the following criteria: IPF 
considered the most likely diagnosis by the regional ILD multidis-
ciplinary team; history of cough; radiological features of honey-
combing in a predominantly basal and subpleural distribution on 
high-resolution CT (HRCT) scanning; bibasal inspiratory crackles 
on auscultation and features of a restrictive ventilatory defect (vital 
capacity (VC) <90% predicted and/or transfer factor for carbon 
monoxide (TLco) <90% predicted).9 10 Due to possible interac-
tions with omeprazole, participants were excluded if they were 
taking warfarin, diazepam, phenytoin or ketoconazole. Participants 
taking active treatments for IPF (eg, pirfenidone or nintedanib) 
had to have been taking these for at least 4 weeks before entry to 
the study. Other exclusion criteria included upper or lower respi-
ratory tract infection or exacerbation of IPF in the 4 weeks prior to 
starting trial treatment, or a history of hepatic cirrhosis.
Patients taking antacids, prokinetics or raft alginates were 
eligible if they had been off these treatments for at least 2 weeks. 
Patients taking a regular PPI who wished to take part were 
eligible if they provided written informed consent to a 2-week 
trial period off treatment, following agreement with their general 
practitioner, and if the trial was tolerated and completed with no 
significant return of upper gastrointestinal (GI) symptoms such 
as reflux, indigestion or heartburn. Patients were asked to refrain 
from using over the counter antacids and to contact the study 
team if these were used, with a view to withdrawal from the 
trial. The online supplementary section contains full details of 
the study schedule (in Table S1), and of the trial's inclusion and 
exclusion criteria. All participants provided written informed 
consent.
study drug, randomisation and blinding
The study compared omeprazole, a substituted benzimidazole 
PPI, with placebo. Participants were randomised 1:1 to receive 
omeprazole 20 mg or matching placebo, to be taken orally twice 
daily before food for 90 days; however, planned treatment dura-
tion between 76 and 90 days was permitted. All other aspects of 
usual patient care were delivered to participants prior to, during 
and after completion of the study. Randomisation was through 
a secure password-protected web-based system administered 
centrally by the Newcastle Clinical Trials Unit. Computer-gener-
ated random permuted blocks of size 12 were used. The partic-
ipant, research team, investigators and sponsor were all blinded 
to allocation. Omeprazole and matched placebo were supplied 
by Victoria Pharmaceuticals, Royal Hospitals, Belfast, UK and 
dispensed by the pharmacy at the Royal Victoria Infirmary, 
Newcastle upon Tyne, UK.
Procedures
Participant demographics, medical comorbidities, smoking 
history and concurrent medications were recorded at screening. 
After informed consent was obtained, baseline assessments 
included physical examination, pulmonary function tests (PFTs) 
and a 6 min walk distance (6MWD). Validated questionnaires to 
assess cough and reflux symptoms were completed by the partici-
pant and included the De Meester reflux-related symptoms ques-
tionnaire (DeMRQ),11 the Reflux Symptoms Index (RSI),12 the 
Gastrointestinal Quality of Life Index (GIQLI)13 and the Leicester 
Cough Questionnaire (LCQ).14 Details of the scoring system for 
each of the questionnaires are described in the supplemental 
section. A higher score indicates better health status for the LCQ 
and GIQLI and the converse is true for the DeMRQ and RSI. 
Participants were also fitted with an ambulatory cough recorder 
(Vitalojak, Vitalograph, Buckingham, UK) for 24 hours.2 15 
PFTs, 6MWD, questionnaires and cough sound recording were 
repeated at the end of the treatment period (ideally these tests 
were performed on day 88 of the 90-day study medication trial 
but could be performed at any point from day 76 onwards).
Oesophageal physiology testing was not mandatory for inclu-
sion; however, for those giving consent to oesophageal proce-
dures these comprised high-resolution oesophageal manometry 
(to measure oesophageal muscular contraction and relaxation of 
the gastro-oesophageal sphincter) and 24 hours pH-impedance 
monitoring (to record regurgitation of gastric contents into the 
oesophagus and participant-reported symptom episodes). Assess-
ments were performed at baseline and at the end of the treat-
ment period. Bronchoscopy with bronchoalveolar lavage (BAL) 
was also not mandatory for inclusion, but where consent for 
the procedure was agreed, this was performed at the end of the 
treatment period. Oesophageal physiology testing and bronchos-
copy with standardised BAL were ideally performed on days 89 
and 90 of the 90-day study medication period, respectively but 
could be performed at any point from day 76 onwards. Details 
of these procedures are given in the online supplemental section.
Participants reported adverse events using a patient diary 
card. Episodes of hospitalisation were reported via telephone. 
All participants were asked to stop the study medication on the 
day they completed their last study procedure. Remaining study 
medication was returned to the pharmacy at the end of the trial 
treatment period and unused supplies were counted.
outcomes
Feasibility outcomes comprised the number of eligible patients, 
the proportion of those willing to take part, the recruitment rate, 
adherence to trial medication and follow-up and the accept-
ability of invasive trial procedures.
Clinical outcome measures were collected to interrogate proof 
of concept with respect to reduction in cough frequency. Twen-
ty-four hours objective cough frequency (total number of coughs/
total recording time in hours) was assessed using an ambulatory 
cough recorder at baseline and the end of the treatment period. 
Sound recordings were compressed using validated custom-
written software to remove silences, background noise and the 
majority of speech.16 The resulting files were then listened to 
and cough sounds manually counted. Awake and asleep cough 
frequencies were calculated.
Additional clinical outcomes included 6MWD and PFTs 
(FEV1, FVC, the FEV1/FVC ratio, TLco and Kco (TLco corrected 
for accessible alveolar volume)). Participant-reported outcomes 
were the total DeMRQ, RSI, GIQLI and LCQ scores. Domain 
scores of the LCQ were also explored.
statistical analysis
Due to the nature of this pilot study no formal sample size calcu-
lation was performed. Recommendations for good practice at 
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Figure 1 Consolidated Standards of Reporting Trials diagram. IPF, idiopathic pulmonary fibrosis; PPI, proton pump inhibitor; CTIMP, clinical trial of 
an investigational medicinal product; IMP, investigational medicinal product. 
the time the study was designed suggested that 20–30 partic-
ipants per treatment group should provide sufficient data to 
assess the feasibility of a trial, investigate the distribution of 
outcome measures and estimate with adequate precision SD of 
key study parameters.17 18
Analyses were performed according to a predefined statistical 
analysis plan (a copy is shown at the end of the online supple-
mental section). Feasibility outcomes were summarised descrip-
tively. Analysis of all clinical outcomes was performed on a 
complete-case basis following the intention-to-treat principle. 
Only observed data were included and there was no imputation 
of missing data. For daytime, night-time and 24 hours cough 
frequency, data were analysed following a log10 transformation. 
A value of 0.1 was added to all night-time cough frequencies 
prior to transformation due to zero coughs being reported for 
some participants. On the logarithmic scale, the difference 
between randomised treatment groups in mean cough frequency 
at end of treatment was estimated using an analysis of covari-
ance (ANCOVA) model, adjusted for baseline cough frequency. 
Model estimates and 95% CIs were then back-transformed to 
give an estimate of the ratio of objective cough frequency in 
the omeprazole group compared with the placebo group at the 
end of treatment. Untransformed secondary clinical outcome 
measures (excluding DeMRQ) were analysed using similar 
ANCOVA models, adjusted for the appropriate baseline value.
Safety data were summarised, for each event, by the worst 
grade reported per participant over the trial treatment period. 
Participants were included in safety analyses if they had taken 
at least one dose of study drug (omeprazole or placebo). 
Oesophageal physiology, bronchoscopy and BAL measures were 
summarised descriptively.
The trial database was locked for final analysis on 16 June 
2017. All analyses were performed using Stata V.14.
regulatory approvals
The clinical trial authorisation was given by the Medicines & 
Healthcare products Regulatory Agency, sponsored by the 
Newcastle upon Tyne Hospitals NHS Foundation Trust and 
supported by the (fully UKCRC-registered) Newcastle Clinical 
Trials Unit. The trial was registered as an International Standard 
Randomised Controlled Trial (ISRCTN07139948), with the EU 
Clinical Trials Register (EudraCT 2013-003301-26) and with 
ClinicalTrials. gov (NCT02085018) prior to the start of the trial. 
The trial was adopted onto the National Institute for Health 
Research portfolio (study ID 15732) and overseen by an inde-
pendent trial steering committee and data monitoring and safety 
committee.
resulTs
Primary feasibility outcomes
Between 1 March 2014 and 19 August 2016, 45 patients were 
recruited, with 23 assigned to receive omeprazole, as illus-
trated in figure 1. In total, 280 patients were assessed for eligi-
bility, 159 (57%) were ineligible or clinically unsuitable and 67 
(24%) declined participation or could not be contacted. The 
most common reasons for ineligibility were unsuitability for a 
trial off PPI (n=34), no cough (n=24) and concomitant use of 
warfarin (n=20). Overall, 25 patients on regular PPI at screening 
consented to a trial off treatment. Of these, nine experienced a 
return of upper GI symptoms and were excluded from the study 
while 16 reported no return of upper GI symptoms and were 
subsequently randomised (eight to each treatment group). The 
average recruitment rate was 1.5 participants per month. A total 
of 13 patients were referred from 6 regional hospitals acting as 
PIC sites; however, none of these were randomised. Following 
randomisation, attrition rate was low with 40 participants (89%) 
348 Dutta P, et al. Thorax 2019;74:346–353. doi:10.1136/thoraxjnl-2018-212102
 o
n
 5 June 2019 by guest. Protected by copyright.
http://thorax.bmj.com/
Thorax: first published as 10.1136/thoraxjnl-2018-212102 on 4 January 2019. Downloaded from 
Interstitial lung disease
Table 1 Baseline demographics and clinical characteristics
omeprazole (n=23) Placebo (n=22)
Female 4 (17%) 6 (27%)
Male 19 (83%) 16 (73%)
Age (years) 71.3 (6.7) 71 (7.3)
Smoking history
  Never smoked 5 (22%) 5 (23%)
  Ex-smoker 18 (78%) 16 (73%)
  Current smoker 0 (0%) 1 (5%)
Pack years* 13.0 (7.5–20.0) 15.0 (7.0–36.0)
BMI (kg/m2) 28.9 (3.8) 29.6 (6.0)
Concomitant pirfenidone 8 10
Concomitant nintedanib 0 2
Concomitant prednisolone† 0 4
Respiratory rate (breaths/min) 21.5 (3.5) 22.4 (3.8)
FEV1 (% predicted) 76.9 (15.4) 78.4 (18.4)
FVC (% predicted) 73.1 (17.1) 77.9 (17.6)
Kco (% predicted) 87.3 (20.9) 83.0 (22.0)
TLco (% predicted) 49.5 (15.7) 48.4 (16.0)
6MWD (m) 416.5 (296.5–485.0) 372.5 (307.6–450.0)
DeMRQ 0.9 (0.8) 1.5 (1.4)
GIQLI 106.3 (17.9) 104.8 (17.8)
LCQ 15.1 (3.2) 15.4 (3.2)
RSI 14.3 (9.6) 17.1 (9.0)
Coughs/hour—24 hours 9.6 (4.2–18.3) 8.9 (6.8–12.8)
Coughs/hour—daytime 13.4 (6.0–24.3) 11.6 (8.5–17.4)
Coughs/hour—night-time 2.1 (0.5–6.9) 2.6 (0.8–9.0)
Data are presented as n (%), mean (standard deviation (SD)) or median (IQR).
*Pack years are shown for participants who were current or ex-smokers and for whom the number of 
pack years was known (n=16 in the omeprazole group and n=15 in the placebo group).
†The doses received by the 4 patients were 4 mg, 6 mg, 10 mg or 15 mg per day. 6MWD was 
performed in 21 of the 22 participants in the placebo group and in all 23 participants in the 
omeprazole group.
6MWD, 6 min walk distance; BMI, body mass index; DeMRQ, De Meester reflux-related symptoms 
questionnaire; GIQLI, Gastrointestinal Quality of Life Index; LCQ, Leicester Cough Questionnaire; RSI, 
Reflux Symptoms Index; TLco, transfer factor for carbon monoxide
completing end of treatment cough monitoring visits (although 
not all participants completed all the other possible study 
assessments).
Median treatment duration was 86 days (IQR 82–90) in the 
omeprazole group and 87.5 days (IQR 79–90) in the placebo 
group. Median tablet return was 14 tablets (IQR 6–25) in the 
omeprazole group and 21.5 tablets (IQR 2–32) in the placebo 
group. Overall, seven participants (three omeprazole, four 
placebo) discontinued treatment early (ie, treatment dura-
tion <76 days). One patient was withdrawn (from the placebo 
group) because of a clinical requirement for PPIs, and use of 
over the counter antacids. No unblinding was required during 
the study.
All randomised participants consented to the non-invasive 
trial procedures (including ambulatory cough monitor, ques-
tionnaires, walk test and PFTs). Completion rate was high with 
most participants completing all non-invasive assessments (three 
participants could not complete PFTs due to poor technique, one 
amputee could not complete a walk test, one participant was 
admitted with sepsis and did not complete tests).
In contrast, a relatively small proportion of participants 
consented to undergo invasive tests (oesophageal manometry, 
24 hours oesophageal pH monitoring and bronchoscopy). Of 
the 45 participants randomised, 13 consented to 24 hours pH 
monitoring, however only 9 completed this at baseline and 6 at 
end of treatment. Thirteen participants consented to undergo 
bronchoscopy but only eight completed the assessment.
Baseline demographics and clinical characteristics were 
approximately balanced between the randomised groups 
(table 1).
Primary clinical outcome
Forty participants (89%) completed cough monitoring before 
and after treatment. Baseline geometric mean 24 hours cough 
frequency (coughs/hour) was 8.2 (95% CI 5.4 to 12.7) and 9.1 
(95% CI 6.8 to 12.2) in the omeprazole and placebo groups, 
respectively. There was a greater reduction in 24 hours cough 
frequency in the omeprazole group compared with placebo. At 
the end of the study geometric mean was 4.6 per hour (95% CI 
2.4 to 8.7) in the omeprazole group and 8.3 per hour (95% CI 5.3 
to 12.9) in the placebo group. Geometric mean cough frequency 
at the end of treatment, adjusted for baseline, was 39.1% lower 
(95% CI 66.0% lower to 9.3% higher) in the omeprazole group 
compared with placebo (table 2). Similar results were observed 
for the relative difference in awake/daytime and asleep/night-
time cough frequency (table 2). Individual participant changes 
in 24 hours, awake/daytime and asleep/night-time objective 
cough frequency are illustrated in figure 2. Absolute cough 
frequency for individuals, before and after treatment, is shown 
in online supplementary figure S1.
secondary outcomes
Participant-reported symptoms of cough (using the LCQ) and 
reflux (using the DeMRQ, the GIQLI and the RSI) were assessed. 
Overall, there was no clinically meaningful difference for partic-
ipant-reported outcome measures between baseline and end of 
treatment in either group. The between-group differences at end 
of treatment for each of the questionnaires are summarised in 
table 3.
Functional status (assessed by PFTs and 6MWD) was obtained 
at baseline and end of treatment for each group (table 4). No 
clinically meaningful difference in PFTs or 6MWD values was 
observed between baseline and end of treatment for either group.
Due to the small numbers of participants consenting to and 
completing the invasive tests (oesophageal manometry, 24-hours 
pH monitoring and bronchoscopy), few data were obtained (see 
online supplementary table S2-S5).
safety
In total, nine serious adverse events were reported across eight 
participants, four allocated to omeprazole and four to placebo. 
Relatedness to trial treatment was judged by the participant’s 
clinician, who was blind to treatment allocation. Three partici-
pants (one omeprazole, two placebo) reported moderate-to-se-
vere abdominal pain, which was deemed an expected serious 
adverse reaction. Two participants died and a further three were 
admitted to hospital while taking part in the study—all were 
considered unrelated to trial treatment. Three participants with-
drew from trial treatment due to abdominal pain (one omepra-
zole, two placebo) and one participant allocated to placebo due 
to hot flushes and fatigue after one dose. Adverse events were 
reported in 16 participants in the omeprazole group (70%) and 
14 in the placebo group (64%). Table 5 details adverse events that 
were reported in more than one participant in the omeprazole 
group. More complete safety data are found in online supple-
mentary table S6-S8 and show no striking differences between 
the groups.
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Table 2 Geometric mean cough frequency (coughs/hour) and the ratio (omeprazole:placebo) of geometric means at the end of treatment, adjusted 
for baseline cough frequency (complete-case analysis set; n=40)
omeprazole (n=20) Placebo (n=20)
baseline
geometric mean (95% CI)
end of treatment
geometric mean (95% CI)
baseline
geometric mean (95% CI)
end of treatment
geometric mean (95% CI)
ratio of geometric means 
at end of treatment, 
adjusted for baseline
(95% CI)
24 hours 8.2 (5.4 to 12.7) 4.6 (2.4 to 8.7) 9.1 (6.8 to 12.2) 8.3 (5.3 to 12.9) 0.609 (0.340 to 1.093)
Awake/daytime 10.8 (6.8 to 17.0) 6.1 (3.2 to 11.8) 11.8 (8.9 to 15.8) 10.7 (6.7 to 17.2) 0.629 (0.354 to 1.119)
Asleep/night-time 1.7 (0.9 to 3.3) 1.1 (0.6 to 2.0) 2.3 (1.1 to 4.7) 2.1 (1.2 to 3.7) 0.553 (0.267 to 1.146)
Figure 2 Individual participant percentage change in 24 hours, awake (daytime) and asleep (night-time) objective cough frequency (coughs/
hour). Data are shown for the complete-case analysis set, n=40. Percentage change = ((end of treatment–baseline/baseline)×100). Each column on 
the x-axis represents a participant. The night-time graph has n=37, as three participants (2 placebo, 1 omeprazole) had zero night-time coughs at 
baseline (end of treatment coughs for these participants were 1.86, 0.32 (placebo) and 0.59 (omeprazole)). 
dIsCussIon
While significant advances have been made in slowing disease 
progression in IPF through the emergence of antifibrotic 
medications such as pirfenidone and nintedanib,19 20 there is a 
pressing need to find solutions for chronic symptom manage-
ment. Chronic cough is one of the most common, distressing and 
notoriously difficult symptoms to control in patients with IPF, 
with a significant impact on quality of life.2 Studies evaluating 
potential therapies for chronic cough in IPF are scarce and have 
shown limited benefit.1 21–23
The hypothesis that GORD perpetuates disease progression 
in IPF has led to studies primarily evaluating the impact of PPIs 
on measures of disease progression and survival.24–27 No defini-
tive conclusion has emerged from these valuable studies, in which 
a range of different methodologies have been employed. To our 
knowledge, this study represents the first pilot RCT of omepra-
zole for the treatment of cough in IPF, while a recent pilot RCT 
has highlighted the feasibility of performing future trials assessing 
the value of laparoscopic antireflux surgery in IPF.28 Our data 
suggested that, on average, cough was reduced in the omeprazole 
group, although this was not statistically significant (as a pilot 
trial, the study was not designed to have sufficient power to detect 
statistically significant differences). The magnitude of the observed 
change in favour of omeprazole is considered clinically important,29 
and is comparable to the effect size observed in studies reporting 
clinically meaningful reductions in objective cough frequency with 
other pharmacological treatments for chronic cough.30 31
The baseline cough frequency was lower than that reported 
in previous studies of IPF. The reasons for this are not clear but 
may relate to the fact that we allowed enrolment of participants 
with self-reported cough, regardless of severity. On balance, we 
believe the average reduction in cough frequency associated with 
omeprazole justifies further assessment of this effect in a larger 
trial.
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Table 3 Between-group differences in participant-reported outcome measures
omeprazole (n=20) Placebo (n=20) Adjusted between-group 
difference (omeprazole minus 
placebo) at end of treatment 
(95% CI)*baseline end of treatment baseline end of treatment
LCQ—total 15.3 (3.3) 15.3 (3.8) 15.1 (3.2) 15.3 (3.6) −0.10 (−2.19 to 1.98)
LCQ—physical domain 5.1 (1.1) 5.0 (1.1) 5.2 (1.0) 5.1 (1.1) 0.02 (−0.54 to 0.57)
LCQ—psychological domain 5.0 (1.4) 5.0 (1.7) 4.8 (1.2) 5.1 (1.3) −0.21 (−1.10 to 0.68)
LCQ—social domain 5.2 (1.1) 5.3 (1.3) 5.1 (1.3) 5.1 (1.4) 0.13 (−0.67 to 0.94)
DeMRQ 0.85 (0.81) 0.65 (1.18) 1.35 (1.14) 1.2 (1.24) ND†
GIQLI 106.7 (18.8) 105.6 (20.6) 104.0 (18.2) 101.2 (21.2) 2.15 (−7.20 to 11.49)
RSI 14.0 (10.2) 14.2 (8.3) 17.0 (9.4) 15.1 (11.0) 0.67 (−4.77 to 6.11)
Data are presented as mean (SD) (complete-case analysis set; n=40).
*Between-group difference at end of treatment was calculated using ANCOVA, adjusted for baseline value and shows the change relative to that in the placebo group. ND: not done
† Not done as model assumptions not satisfied. For LCQ and GIQLI a higher score indicates improvement, for DeMRQ and RSI a lower score indicates improvement.
DeMRQ, De Meester reflux-related symptoms questionnaire; GIQLI, Gastrointestinal Quality of Life Index; LCQ, Leicester Cough Questionnaire; RSI, Reflux Symptoms Index.
Table 4 Pulmonary function tests and 6MWD at baseline and end of treatment
omeprazole (n=20) Placebo (n=20) Adjusted between group 
difference (omeprazole minus 
placebo) at end of treatment 
(95% CI)baseline end of treatment baseline end of treatment
FEV1 n=19* n=20
Measured (L) 2.10 (0.53) 2.05 (0.63) 1.99 (0.57) 2.07 (0.52) −0.12 (−0.25 to −0.002)†
% predicted 78.6 (15.7) 75.8 (18.0) 77.9 (19.2) 82.6 (19.4) −7.4 (−14.6 to −0.2)† 
FVC n=19* n=20
Measured (L) 2.57 (0.71) 2.48 (0.77) 2.50 (0.65) 2.53 (0.66) −0.11 (−0.21 to − 0.02)
% predicted 75.0 (17.9) 71.1 (18.7) 77.9 (17.6) 78.1 (18.3) −5.1 (−9.4 to −0.8)
FEV1/FVC n=19* n=20
% 0.82 (0.04) 0.83 (0.07) 0.80 (0.13) 0.83 (0.07) 0.00 (−0.04 to 0.04)
Kco n=18*, ‡ n=18§
Measured (mmol/min/kPa/L) 1.18 (0.29) 1.21 (0.31) 1.11 (0.27) 1.04 (0.28) 0.11 (0.002 to 0.22)
% predicted 90.7 (21.7) 94.3 (23.1) 85.3 (22.6) 80.3 (22.7) 9.3 (0.9 to 17.6)
TLco n=18*, ‡ n=18§ 
Measured (mmol/min/kPa) 4.42 (1.60) 4.39 (1.53) 3.98 (1.28) 3.80 (1.43) 0.19 (−0.30 to 0.68)
% predicted 52.4 (15.8) 52.1 (14.4) 50.1 (15.8) 47.7 (16.2) 2.5 (−3.1 to 8.0)
6MWD n=19* n=19¶
Measured (metres) 408.5 (102.6) 386.3 (130.6) 372.4 (112.7) 381.1 (109.9) −30.4 (-68.9 to 8.1)**
Data are presented as mean (SD).
*Assessments not performed as participant in hospital with sepsis.
†Model has poor fit due to outlying values for one participant. 
‡Participant unable to breath-hold, hence gas transfer not measurable.
§ One participant unable to perform full PFTs and one participant had poor technique in lung function at baseline. Unable to measure gas transfer factors.
¶Walk test not performed due to above knee amputation.
** Model has poor fit due to an outlying value for one participant. 
6MWD, 6 min walk distance; TLco, transfer factor for carbon monoxide.  
Omeprazole appears to have been well tolerated in this study. 
Stomach acid is thought to eradicate ingested bacteria, leading 
to the concern that PPIs may promote retention of microbes 
in gastric fluid, which in turn can be micro-aspirated into the 
lungs. Higher rates of lower respiratory tract infection have been 
described in patients prescribed PPIs, although some of the data 
pertain to post hoc analyses, with the inherent limitations asso-
ciated with this approach.26 27 32–34 While adverse events were 
generally evenly distributed in the two groups, lower respiratory 
tract infections were twice as common in the omeprazole group, 
although the numbers involved (six in the omeprazole group, 
three in the placebo group) raise the possibility that the obser-
vation arose by chance. Accurate discrimination of true alveolar 
infection from the natural history of progressive fibrosis is diffi-
cult in IPF and infection was assessed on clinical suspicion in 
this study, without microbiological confirmation. Interestingly, 
FEV1 and FVC were significantly lower in the omeprazole group 
(table 4). However, an apparent trend in the opposite direction 
(ie, favouring omeprazole) was observed for Kco (table 4). On 
balance, PPIs appear to be well tolerated in IPF, but future trials 
should monitor lung function and rates of lower respiratory tract 
infection.
If it is accepted that tolerance of omeprazole, and its potential 
to reduce cough, justify pursuit of a larger RCT, the next ques-
tion is whether such a study is likely to be feasible? On the basis 
of our evidence we believe such a study is eminently feasible, 
although several issues will require consideration. These will 
include taking account of the proportion of patients already 
taking long-term PPIs. There are few indications for long-term 
PPIs, so aligning patients’ prescriptions with guidelines should 
be expected to allow their discontinuation. The welcome prolif-
eration of available clinical trials in IPF may also reduce the 
potential pool of patients available to a larger trial of PPIs in 
IPF. Our clinic is a regional referral centre for antifibrotic drugs 
and therefore sees a high volume of patients, and even under 
these circumstances we took two and a half years to generate 
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Table 5 Adverse events (by preferred term) reported in more than 
one omeprazole participant
omeprazole (n=23) Placebo (n=22)
n % n %
Lower respiratory tract infection 6 26 3 14
Vomiting 2 9 4 18
Urinary tract infection 2 9 0 0
Abdominal pain 3 13 3 14
Cough 3 13 1 5
primary clinical outcome data for 40 participants. Future trial 
design will therefore require to incorporate realistic time scales 
for recruitment.
Our data suggest that compliance with treatment was good. 
Non-invasive, portable cough monitoring was readily accepted 
by participants and there were no technical failures. Patients 
with IPF find cough intrusive and disabling.2 35 Cough would 
therefore appear to be a worthwhile end point for trials in IPF. 
However, although average cough frequency was lower in the 
omeprazole group, no changes were seen in participant-reported 
cough or reflux questionnaires. The lack of change in reflux 
symptoms is not especially surprising when those who could 
not tolerate PPI withdrawal were excluded from further study. 
While a reduction in objective cough frequency would satisfy 
the rigour required of an objective outcome measure in RCTs, if 
patients’ experience of cough is apparently unaffected the bene-
fits are harder to envisage. One potential explanation is that the 
LCQ was never developed for use in patients with IPF and it 
is likely that it does not capture the true impact of coughing 
in this patient group, and in particular the interaction between 
cough and breathlessness. The relationship between objective 
cough frequency and perceived cough severity is complex. It 
may be advisable for future, larger trials to incorporate other 
cough and/or quality of life measures alongside objective cough 
monitoring, such as cough severity visual analogue scales and a 
generic quality of life tool.
In contrast to the acceptability of cough monitoring, our 
data suggest that, in studies primarily focused on cough, inva-
sive oesophageal studies and bronchoscopy were not favoured 
by participants with IPF. Less than one-third of participants 
were willing to have these assessments. No reliable trends were 
observed from the data obtained, although two participants in 
the omeprazole group had bacterial pathogens cultured from 
BAL, reinforcing the suggestion that lower respiratory tract 
infection should be an embedded part of safety assessments in 
future trials.
Whether we used the most appropriate PPI, in the most appro-
priate dose, for the most appropriate length of time is open to 
debate. Twice-daily omeprazole was selected on the basis of 
good 24 hours acid suppression,36 given that omeprazole appears 
to suppress acid secretion effectively for 12 hours. Omeprazole 
induces CYP1A2 and could theoretically reduce circulating 
pirfenidone concentrations (patients in this study were informed 
of this theoretical risk ahead of randomisation).37 Future trials 
should consider use of alternative PPIs without the potential for 
drug interaction with pirfenidone, in particular. The 3-month 
duration of treatment was largely pragmatic.
Whether our participants were representative of ‘real-life’ IPF 
is also open to question. Our cohort does seem broadly reflective 
of patients with IPF recruited to RCTs in terms of mean age and 
baseline FVC, TLco and 6MWD. We recruited more men than 
women, in keeping with the sex distribution of IPF,38 but our 
population showed even higher male distribution than in most 
trials. Nintedanib was only recently available to patients in the 
UK at the time of the trial, and use in this study was therefore 
lower than in current practice.
In summary, we believe these data support the pursuit of a 
larger multicentre trial to determine whether PPIs can reduce 
cough in IPF and provide a suite of background information to 
inform rational design of such a trial. Future trials should be 
large enough to mitigate risks to recruitment and should specifi-
cally incorporate assessments of lower respiratory tract infection 
and lung function as part of safety analysis.
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